Cytoo

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
CYTOO is a preclinical stage drug discovery company focused on muscle disorders and operating largely through external alliances.

CYTOO uses its proprietary in vitro muscle platform MyoScreen for its own drug discovery pipeline and also gives access to MyoScreen to third parties for target and drug discovery, gene therapy candidate screening and potency assay development.
CYTOO has a strong expertise in muscle disease modeling with secured access to various patient myoblasts (myopathies, metabolic and mitochondrial disorders…).

MyoScreen has been designed as an industrial platform for drug discovery by combining high-throughput, high content, robustness and predictability. MyoScreen is compatible with conventional functional genomics tools. MyoScreen is continuously validated by an increasing number of partnerships (Publicly disclosed: AskBio, Axcella, Daiichi Sankyo,Pfizer) which continue to endorse the MyoScreen technology in their drug/target development programs.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
CYT-9733
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
CYTOO